Natural Aldose Reductase Inhibitor: A Potential Therapeutic Agent for Non-alcoholic Fatty Liver Disease
- 1 January 2020
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 21 (6), 599-609
- https://doi.org/10.2174/1389450120666191007111712
Abstract
Aldose reductase (AR) has been reported to be involved in the development of nonalcoholic fatty liver disease (NAFLD). Hepatic AR is induced under hyperglycemia condition and converts excess glucose to lipogenic fructose, which contributes in part to the accumulation of fat in the liver cells of diabetes rodents. In addition, the hyperglycemia-induced AR or nutrition-induced AR causes suppression of the transcriptional activity of peroxisome proliferator-activated receptor (PPAR) a and reduced lipolysis in the liver, which also contribute to the development of NAFLD. Moreover, AR induction in non-alcoholic steatohepatitis (NASH) may aggravate oxidative stress and the expression of inflammatory cytokines in the liver. Here, we summarize the knowledge on AR inhibitors of plant origin and review the effect of some plant-derived AR inhibitors on NAFLD/NASH in rodents. Natural AR inhibitors may improve NAFLD at least in part through attenuating oxidative stress and inflammatory cytokine expression. Some of the natural AR inhibitors have been reported to attenuate hepatic steatosis through the regulation of PPAR alpha-mediated fatty acid oxidation. In this review, we propose that the natural AR inhibitors are potential therapeutic agents for NAFLD.Keywords
This publication has 117 references indexed in Scilit:
- Nrf2 deletion causes “benign” simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat dietLipids in Health and Disease, 2013
- Aldose Reductase Is Involved in the Development of Murine Diet-Induced Nonalcoholic SteatohepatitisPLOS ONE, 2013
- Long‐term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathyDiabetic Medicine, 2012
- Treatment with Ginger Ameliorates Fructose-Induced Fatty Liver and Hypertriglyceridemia in Rats: Modulation of the Hepatic Carbohydrate Response Element-Binding Protein-Mediated PathwayEvidence-Based Complementary and Alternative Medicine, 2012
- Inhibition of Aldose Reductase Activates Hepatic Peroxisome Proliferator-Activated Receptor-αand Ameliorates Hepatosteatosis in Diabetic db/db MiceExperimental Diabetes Research, 2012
- Myricetin Increases Hepatic Peroxisome Proliferator-Activated ReceptorαProtein Expression and Decreases Plasma Lipids and Adiposity in RatsEvidence-Based Complementary and Alternative Medicine, 2012
- Kaempferol Regulates the Lipid-Profile in High-Fat Diet-Fed Rats through an Increase in Hepatic PPARαLevelsPlanta Medica, 2011
- PPARα Expression Protects Male Mice from High Fat–Induced Nonalcoholic Fatty Liver1–3Journal of Nutrition, 2011
- A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice.JCI Insight, 1998
- An Inhibitor of Aldose Reductase and Sorbitol Accumulation fromAnthocepharus chinensisPlanta Medica, 1998